Ask AI

PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options to Broader Patient Populations

Learn how experts incorporate the newest evidence from ASCO 2021 on PARP inhibitor&ndash based combinations into optimal management of prostate cancer with an on-demand webcast from a live webinar plus an expert commentary podcast and downloadable slidesets with ExpressPoints slides.

Share

Program Content

Activities

<i>EP</i>: Prostate Ca PARPi Combos
ExpressPoints
PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options to Broader Patient Populations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2021

PARPi monotherapy
Single-Agent PARP Inhibitors in Prostate Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

Rationale for PARPi Combos
Understanding the Interdependencies of Targeted Pathways: Rationale for PARP Inhibitor Combinations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

PARPi Combos in Prostate Cancer
PARP Inhibitor Combinations in Prostate Cancer: Current Clinical Evidence and Key Ongoing Trials
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2021

No activities added yet

Activities

PARPi Combo Evidence in PCa
Expanding the Role of PARP Inhibitors in Prostate Cancer—Innovative Combination Strategies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2021

Activities

Q&A: PARPi Combos in PCa
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2021

Podcast Pearls: PARPi Combos in PCa
Podcast Pearls: Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
Multimedia
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2021

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.